SamanTree Medical SA raises 4.5M CHF in Series A financing13.01.2015 08:25
SamanTree Medical, a digital microscopy company developing advanced fresh-tissue microscopy scanners, announces that it has raised CHF 4.5 million from private investors in a Series A Financing round.
“The funding will enable us to accelerate the development and commercialization of SamanTree’s advanced intra-operative digital pathology scanner, for rapid and convenient assessment of cancer tissue during oncologic surgeries, resulting potentially in a higher rate of complete cancer cure, and reduction of reoperations“, said Dr. Davor Kosanic, CEO of SamanTree Medical.
The financial resources will be used to advance SamanTree Medical’s leading-edge fresh tissue scanner development through clinical pathway, regulatory approvals and industrialization. SamanTree Medical´s microscopy technology is based on several years of research and development at the prestigious Ecole Polytechnique Fédérale de Lausanne (EPFL). The fresh-tissue scanner technology allows surgeons to establish a direct communication channel to pathologists and obtain an ultra-rapid histopathological assessment of cancer tissue during the surgery, with the aim to improve surgical workflow, treatment decisions and resection accuracy, while potentially reducing the re-operation rates and assuring patients of total cancer removal .
The investors and innovators additionally appointed Ms Malgosia Iwankowska and Mr. Jan Dekker as members of the Board of Directors.
“I am very pleased and proud of having such high profile executives directly involved with SamanTree Medical. They bring a wealth of experience with strategic planning and operations in the medical devices industry both in Europe and in the U.S. This is an invaluable asset for the continuing development of the company.” Said Dr. Bastien Rachet, CTO of SamanTree Medical
About SamanTree Medical:
SamanTree Medical SA is a digital microscopy company and spin-off of the EPFL (CH). SamanTree develops fresh-tissue microscopy scanners, with the mission to enable point-of-care digital pathology for complete tumor resection guidance. Early-stage cancer diagnosis and subsequent complete surgical resection of the tumor compose the therapy with highest chances for cancer free. SamanTree’s mission is to enable intra-operative digital pathology, to improve surgical workflow, treatment decisions and resection accuracy, while potentially reducing the re-operation rates and cutting the overall cost of procedures. The digitization of the intra-operative pathological examination has the potential to establish PACS (Picture Archiving and Communication Systems) as standard for pathology.